RxDoctor Payments Data

Frank Bucciero, OD

Optometrist · Springfield, NJNPI 1861470601

Payments from drug & device makers

What this record shows

This record is dominated by other: $54,010 of the $56,619 with a category attached, or 95.4%. Alcon accounts for 95.4% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $54,631, more than ten times the $392 reported in 2019. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,619in general payments, 2019–2025

Across 33 payments — averaging $1715.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$54K
  • AbbVie$509
  • Bausch & Lomb Americas Inc.$378
  • Tarsus Pharmaceuticals, Inc.$356
  • Sight Sciences, Inc.$345
  • Glaukos Corporation$276
  • plus $746 from 10 others

What the payments were for

  • Food & beverage$2,6095%
  • Other$54,01095%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,619 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$128,528
Medicare patients
527
Services billed
1,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod35$13,993
MieboPerfluorohexyloctane/Pf11$12,168
LumiganBimatoprost13$4,002
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$3,360
SimbrinzaBrinzolamide/Brimonidine Tart12$2,645
Latanoprost172$2,320
Travoprost16$1,546
Timolol Maleate13$1,520
Brimonidine Tartrate42$961
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$800
Dorzolamide Hcl11$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Miebo$378$26,16046 claims
AbbVieLumigan$509$4,00213 claims
AlconSimbrinza$54,010$2,64512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.

Other optometrist in Springfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →